NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,010 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on November 3, 2026 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of Neurogene’s common stock on the Grant Date. The Inducement Grant will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and 1/48 of the total award each month thereafter over the following three years, subject to the employee’s continued employment with Neurogene through the applicable vesting dates.
About Neurogene
Neurogene (Nasdaq: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.